INNO and IP40 Related Headlines
Go Back- Innocan Pharma receives third consecutive FDA fee waiver for dog pain drug
- FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
- Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
- Innocan Pharma anticipates NYSE American listing around January 7
- Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
INNO and IP40 Related Press Releases
Go Back- FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
- Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
- Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
